Abstract Objective To summarize the clinical characteristics and evaluate the feasible treatments of primary breast lymphoma (PBL). Methods The clinical data of 34 PBL patients (age 24-79 years) who were treated in our hospital between April 2006 and December 2013 were reviewed. Of these 34 patients, 18 had stage ⅠE PBL and 16 had stage ⅡE PBL. Pathological types included diffuse large B cell lymphoma (29 patients), anaplastic large cell lymphoma (2 patients), marginal zone lymphoma (2 patients), and mantle cell lymphoma (1 patient). Two patients underwent surgery, four patients received chemotherapy alone, five patients received chemoradiotherapy, fourteen patients underwent surgery plus chemotherapy, and nine patients underwent surgery plus chemoradiotherapy. The 5-year overall survival (OS) and progression-free survival (PFS) rates were determined by the Kaplan-Meier estimator. Results During follow-up, 26 patients were alive without lymphoma and 8 patients had died by the end of follow-up (7 died from lymphoma and 1 died from chemotherapy-related hepatic failure). Among the 6 patients who relapsed, 5(83.3%) had recurrence within the first 2 years of treatment. In particular, 1 patient who had bilateral breast involvement developed left breast relapse after bilateral mastectomy and chemotherapy, 2 patients had bone marrow metastasis, 1 patient had lung and mediastinal lymph node metastases, and 2 had skin relapse. The 5-year OS and PFS rates of all patients were 75% and 75%, respectively. Conclusions Since PBL is a rare malignancy, its overall prognosis is fair and the incidence of local relapse is low with chemotherapy alone or in combination with other treatments. However, further studies on the development of more effective treatments will be required for patients who have failed the existing treatments.
Zhang Na,Liu Peng,Lu Ke et al. Primary breast lymphoma:a prognostic analysis and literature review[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 914-917.
Zhang Na,Liu Peng,Lu Ke et al. Primary breast lymphoma:a prognostic analysis and literature review[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 914-917.
[1] Aviv A,Tadmor T,Polliack A.Primary diffuse large B-cell lymphoma of the breast:looking at pathogenesis,clinical issues and therapeutic options[J].Ann Oncol,2013,24(9):2236-2244.DOI:10.1093/annonc/mdt192. [2] Caon J,Wai ES,Hart J,et al. Treatment and outcomes of primary breast lymphoma[J].Clin Breast Cancer,2012,12(2):412-419.DIO:10.1016/j.clbc.2012.07.006. [3] Surov A,Holzhausen HJ,Wienke A,et al. Primary and secondary breast lymphoma:prevalence,clinical signs and radiological features[J].Br J Radiol,2012,85(1):e195-205.DOI:10.1259/bjr/78413721. [4] Arber DA,Simpson JF,Weiss LM,et al. Non-Hodgkin’s lymphoma involving the breast[J].Am J Surg Pathol,1994,18(2):288-295. [5] Validire P,Capovilla M,Asselain B,et al. Primary breast non-Hodgkin’s lymphoma:a large single center study of initial characteristics,natural history,and prognostic factors[J].Am J Hematol,2009,84(1):133-139.DOI:10.1002/ajh.21353. [6] Yhim HY,Kang HJ,Choi YH,et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma, Consortium for Improving Survival of Lymphoma (CISL) study[J].BMC Cancer,2010,10(2):321.DOI:10.1186/1471-2407-10-321. [7] Shao YB,Sun XF,He YN,et al. Clinicopathological features of thirty patients with primary breast lymphoma and review of the literature[J].Med Oncol,2015,32(2):448.DOI:10.1007/s12032-014-0448-z. [8] Hosein PJ,Maragulia JC,Salzberg MP,et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era[J].Br J Haematol,2014,165(3):358-363.DOI:10.1111/bjh.12753. [9] Cheah CY,Campbell BA,Seymour JF.Primary breast lymphoma[J].Cancer Treat Rev,2014,40(8):900-908.DOI:10.1016/j.ctrv.2014.05.010. [10] Dobrotina AF,Zlotnikova ZB.Generalized sarcomatosis (lymphosarcomatosis) in pregnancy with unusual bilateral involvement of the breasts[J].Vopr Onkol,1959,5(3):613-616. [11] Wiseman C,Liao KT.Primary lymphoma of the breast[J].Cancer,1972,29(6):1705-1712.DOI:10.1002/1097-0142(197206)29:6<1705:AID-CNCR2820290640>3.0.CO,2-I. [12] Hugh JC,Jackson FI,Hanson J,et al. Primary breast lymphoma. An immunohistologic study of 20 new cases[J].Cancer,1990,66(12):2602-2611.DOI:10.1002/1097-0142(19901215)66:12<2602::AID-CNCR2820661224>3.0.CO,2-U. [13] Jung SP,Kim M,Han KM,et al. Primary breast lymphoma:a single institution’s experience[J].J Korean Surg Soc,2013,84(5):267-272.DOI:10.4174/jkss.2013.84.5.267. [14] 段明辉,曹欣欣,蔡华聪,等.14例原发乳腺淋巴瘤患者临床分析[J].中华血液学杂志,2014,35(10):918-921.DOI:10.3760/cma.j.issn.0253-2727.2014.10.010. Duan MH,Cao XX,Cai HC,et al. Clinical analysis of 14 cases of primary breast lymphoma[J].Chin J Hematol,2014,35(10):918-921.DOI:10.3760/cma.j.issn.0253-2727.2014.10.010. [15] Franco PF,Lavernia J,Aguiar-Bujanda D,et al. Primary Breast Lymphoma:analysis of 55 cases of the spanish lymphoma oncology group[J].Clin Lymph Leuk,2016,9(16)30560-2.DOI:10.1016/j.clml.2016.09.004. [16] Carbone PP,Kaplan HS,Musshoff K,et al. Report of the committee on Hodgkin’s disease staging classification[J].Cancer Res,1971,31(11):1860-1861. [17] Harris NL,Jaffe ES,Diebold J,et al. The world health organization classification of hematological malignancies report of the clinical advisory committee meeting,airlie house,virginia,november 1997[J].Mod Pathol,2000,13(2):193-207.DOI:10.1038/sj/thj/6200013. [18] Miller TP,Dahlberg S,Cassady JR,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin′s lymphoma[J].N Engl J Med,1998,339(1):21-26.DOI:10.1056/NEJM199807023390104. [19] Cheson BD,Horning JS,Coiffier B,et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J].J Clin Oncol,1999,17(4):1244-1253.DOI:10.1200/jco.1999.17.4.1244. [20] Yhim HY,Kim JS,Kang HJ,et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B cell lymphoma in patients treated with rituximab plus chemotherapy[J].Int J Cancer,2012,131(1):235-243.DOI:10.1002/ijc.26352. [21] Avilés A,Castaňeda C,Neri N,et al. Rituximab and dose dense chemotherapy in primary breast lymphoma[J].Haematologica,2007,92(8):1147-1148.DOI:10.3324/haematol.10892. [22] Avilés A,Delgado S,Nambo MJ,et al. Primary breast lymphoma:results of a controlled clinical trial[J].Oncology,2005,69(3):256-260.DOI:10.1159/000088333. [23] Jennings WC,Baker RS,Murray SS,et al. Primary breast lymphoma:the role of mastectomy and the importance of lymph node status[J].Ann Surg,2007,245(5):784-789.DOI:10.1097/01.sla.0000254418.90192.59. [24] Habermann TM,Weller EA,Morrison VA,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma[J].J Clin Oncol,2006,24(19):3121-3127.DOI:10.1200/JCO.2005.05.1003. [25] Zhang N,Cao C,Zhu Y,et al. Primary breast diffuse large B-cell lymphoma in the era of rituximab[J].Oncol Targets Ther,2016,9:6093-6097.
2017, Vol. 26 
